Markets

Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension

Sep 23, 2026 · 04:02 PM ET· updated 1d ago

– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical

Why It Matters

Gossamer Bio asked the FDA to review their new heart disease medicine. This shows the company is moving forward with testing and approval.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GOSS10.94

-0.05 (-0.45%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.